GlaxoSmithKline plc's (GSK) "Buy" Rating Reaffirmed at Beaufort Securities


's stock had its "buy" rating reissued by research analysts at Beaufort Securities in a research note issued to investors on Friday. They currently have a GBX 1,750 target price on the stock.



from Biotech News